Abstract
There has been considerable progress in the systemic treatment of cancer because of the rapid development and clinical application of molecular targeted agents. Although patients with a particular type and stage of cancer are often treated as a single group, more-specific therapy is being considered, as subsets of these patients who are more likely to benefit from treatment with particular agents are being identified. We previously introduced the concept of 'oncogene addiction' to explain how some cancers that contain multiple genetic, epigenetic, and chromosomal abnormalities are dependent on or 'addicted' to one or a few genes for both maintenance of the malignant phenotype and cell survival. Thus, reversal of only one or a few of these abnormalities can inhibit cancer cell growth and in some cases translate to improved survival rates. This review summarizes current experimental and clinical evidence for the concept of oncogene addiction and describes molecular mechanisms that may explain this phenomenon. In addition, we discuss how high-throughput screening methods, including gene-expression profiling and proteomics, and emerging methods for analyzing complex cellular networks can be used to identify the state of oncogene addiction, i.e. the 'Achilles' heel,' in specific cancers. Finally, we discuss the use of molecular targeted agents in combination with other anticancer agents as a strategy to optimize therapy and prevent disease recurrence.
Key Points
-
'Oncogene addiction' describes the phenomenon by which some cancers that contain multiple genetic and epigenetic abnormalities remain dependent on (addicted to) one or a few genes for both maintenance of the malignant phenotype and cell survival
-
Evidence that supports the concept of oncogene addiction has now been obtained in three diverse systems: 1) genetically engineered mouse models of human cancer, 2) mechanistic studies in human cancer cell lines, and 3) clinical trials with specific molecular targeted agents
-
'Network theory' and other techniques of systems biology may provide methods for analyzing the entire circuitry of cancer cells and thus facilitate identification of pathways of oncogene addiction in specific types of human cancer
-
These insights will guide the development and clinical application of novel molecular targeted agents
-
Treatment regimens that combine molecular targeted agents with other anticancer agents could provide the optimal strategy for treating and preventing cancer
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Weinstein IB et al. (1997) Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res 3: 2696–2702
Weinstein IB (2000) Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 21: 857–864
Weinstein IB (2002) Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science 297: 63–64
Sawyers C (2004) Targeted cancer therapy. Nature 432: 294–297
Kaelin WG Jr (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5: 689–698
Felsher DW and Bishop JM (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4: 199–207
Huettner CS et al. (2000) Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 24: 57–60
Chin L et al. (1999) Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468–472
Jackson EL et al. (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243–3248
Pelengaris S et al. (2002) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109: 321–334
Jain M et al. (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297: 102–104
Moody SE et al. (2002) Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2: 451–461
Moody SE et al. (2005) The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8: 197–209
D'Cruz CM et al. (2001) c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7: 235–239
Gunther EJ et al. (2003) Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 17: 488–501
Colomer R et al. (1994) erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 70: 819–825
Zhou P et al. (1995) Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 11: 571–580
Arber N et al. (1997) Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 57: 1569–1574
Kornmann, M et al. (1999) Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res 59: 3505–3511
Sauter ER et al. (1999) Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res 59: 4876–4881
Hui AB et al. (2005) Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res 65: 8125–8133
Aoki K et al. (1997) Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol Carcinog 20: 251–258
Brummelkamp TR et al. (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2: 243–247
Verma UN et al. (2003) Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 9: 1291–1300
Li K et al. (2003) Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. Cancer Res 63: 3593–3597
Sharma A et al. (2005) Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65: 2412–2421
Miller AJ et al. (2004) Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res 64: 509–516
Slamon DJ et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792
Piccart-Gebhart MJ et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659–1672
Baselga J and Albanell J (2001) Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12 (Suppl 1): S35–S41
Hughes TP et al. (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349: 1423–1432
Shepherd FA et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132
Demetri GD et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472–480
Moore MJ (2005) Brief communication: a new combination in the treatment of advanced pancreatic cancer. Semin Oncol 32: 5–6
Taron M et al. (2005) Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11: 5878–5885
Lynch TJ et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139
Pao W et al. (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306–13311
Mellinghoff IK et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012–2024
Baselga J et al. (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23: 5568–5577
Cunningham D et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345
Miller KD et al. (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792–799
Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342
Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434
Gorre ME et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876–880
Kobayashi S et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786–792
La Rosee P et al. (2002) Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec®, STI571). Cancer Res 62: 7149–7153
Kerr JF et al. (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer 73: 2013–2026
Mills GB et al. (2001) Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA 98: 10031–10033
Sordella R et al. (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163–1167
Cappuzzo F et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643–655
Dowell JE and Minna JD (2004) The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy. Nat Clin Pract Oncol 1: 2–3
Paddison PJ et al. (2004) A resource for large-scale RNA-interference-based screens in mammals. Nature 428: 427–431
Zhang SZ et al. (2005) Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther 4: 1577–1584
Varga AC and Wrana JL (2005) The disparate role of BMP in stem cell biology. Oncogene 24: 5713–5721
Stadler WM (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 104: 2323–2333
Garraway LA et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117–122
Berman, DM et al. (2002) Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297: 1559–1561
Radtke F and Clevers H (2005) Self-renewal and cancer of the gut: two sides of a coin. Science 307: 1904–1909
Ottino JM (2004) Engineering complex systems. Nature 427: 399
Bray D (2003) Molecular networks: the top-down view. Science 301: 1864–1865
Alon U (2003) Biological networks: the tinkerer as an engineer. Science 301: 1866–1867
Huang S (1999) Gene expression profiling, genetic networks, and cellular states: an integrating concept for tumorigenesis and drug discovery. J Mol Med 77: 469–480
Baak JP et al. (2005) Genomics and proteomics—the way forward. Ann Oncol 16 (Suppl 2): ii30–44
Wittekind C and Neid M (2005) Cancer invasion and metastasis. Oncology 69 (Suppl 1): 14–16
Cheng JQ et al. (2005) The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24: 7482–7492
Bergers G and Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401–410
Jonkers J and Berns A (2004) Oncogene addiction: sometimes a temporary slavery. Cancer Cell 6: 535–538
Fan QW et al. (2003) Combinatorial efficacy achieved through two-point blockade within a signaling pathway—a chemical genetic approach. Cancer Res 63: 8930–8938
Frantz S (2005) Drug discovery: playing dirty. Nature 437: 942–943
Whitesell L and Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761–772
Adams J (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5: 417–421
McCormick F (2001) Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 1: 130–141
Egger G et al. (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457–463
Balch C et al. (2005) Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 4: 1505–1514
Sandor V et al. (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8: 718–728
Acknowledgements
This work was supported by awards to IBW from the National Foundation for Cancer Research, the Entertainment Industry–National Colorectal Research Alliance, and the TJ Martell Foundation, and awards to AKJ from the National Cancer Institute (5K23CA101669) and the National Institutes of Health (MO1-RR00645).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Weinstein, I., Joe, A. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. Nat Rev Clin Oncol 3, 448–457 (2006). https://doi.org/10.1038/ncponc0558
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0558
This article is cited by
-
Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
Journal of Molecular Medicine (2024)
-
Exploring the adsorption performance of doped graphene quantum dots as anticancer drug carriers for cisplatin by DFT, PCM, and COSMO approaches
Structural Chemistry (2023)
-
Formulation Development, Optimization, and Characterization of Entrectinib-Loaded Supersaturable Self-Nanoemulsifying Drug Delivery Systems
BioNanoScience (2023)
-
Mechanisms of breast cancer metastasis
Clinical & Experimental Metastasis (2022)
-
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)
Investigational New Drugs (2022)